When you then switch to tirzepatide, you are now stimulating both GLP-1 and GIP receptors
M., Melnikova, T
Preventive and treatment measures:Regular monitoring of blood pressure: During the use of GLP-1 , patients should regularly monitor blood pressure changes, promptly detect blood pressure abnormalities, and take corresponding measures.Adjusting the dosage of antihypertensive drugs: For patients with pre-existing hypertension, it may be necessary to adjust the dosage of antihypertensive drugs in a timely manner under the guidance of a doctor based on blood pressure monitoring results when using GLP-1 drug

Research has identified these alarming vision-related risks associated with GLP-1 medications: Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication

Bibcode:2014NatCo...5.3936B
The actual milligram dose depends entirely on the concentration of the solution